| Oct 27, 2025 | finance.yahoo.com | Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics |
| Oct 10, 2025 | finance.yahoo.com | 8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors |
| Oct 9, 2025 | finance.yahoo.com | Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $5.2 Billion Buyout |
| Oct 2, 2025 | finance.yahoo.com | Assessing 89bio (ETNB) Valuation Following a 60% Share Price Rally |
| Oct 1, 2025 | finance.yahoo.com | Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash |
| Sep 30, 2025 | finance.yahoo.com | 89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal |
| Sep 19, 2025 | finance.yahoo.com | 89Bio (ETNB) Soars 86 Percent to Historic High on $3.5-Billion Roche Merger |
| Sep 19, 2025 | finance.yahoo.com | Raymond James cuts 89bio to “market perform” after Roche’s $14.50 per share deal |
| Sep 18, 2025 | www.globes.co.il | תאגיד רוש ירכוש את חברת 89bio תמורת 2.4 מיליארד דולר מיידית, עם אופציה להכנסות נוספות עד סכום כולל לעסקה של 3.5 מיליארד דולר ● 89bio פועלת בשוק הענק של כבד שומני, אך רוש מתעניינת לא פחות במוצר של החברה לטיפול גם במחלות נוספות |
| Sep 18, 2025 | www.calcalistech.com | Roche strikes $3.5 billion deal for U.S.-Israeli biotech 89bio | CTech |
| Sep 18, 2025 | finance.yahoo.com | Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds |
| Sep 18, 2025 | finance.yahoo.com | 89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. |
| Sep 18, 2025 | finance.yahoo.com | RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline |
| Sep 18, 2025 | finance.yahoo.com | 89bio, Inc. Announces Agreement to be Acquired by Roche |
| Sep 18, 2025 | www.wsj.com | Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion |
| Sep 18, 2025 | en.globes.co.il | The company, which was founded in Israel, has a drug for treatment of fatty liver in phase III trials, which was initially an asset of Teva. |
| Sep 18, 2025 | finance.yahoo.com | Stocks to Watch Recap: Intel, FedEx, Meta, Darden Restaurants |
| Sep 18, 2025 | finance.yahoo.com | Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout |
| Sep 18, 2025 | finance.yahoo.com | Sector Update: Health Care Stocks Advance Late Afternoon |
| Sep 18, 2025 | finance.yahoo.com | Stocks Gain Pre-Bell as Fed Lowers Rates, Signals Further Policy Easing in 2025 |
| Sep 17, 2025 | finance.yahoo.com | A Closer Look at 89bio (ETNB) Valuation Following Recent Share Price Drift |
| Sep 8, 2025 | finance.yahoo.com | H.C. Wainwright Backs 89bio (ETNB) with Buy Rating |
| Sep 5, 2025 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Aug 28, 2025 | finance.yahoo.com | 89bio to Participate in Upcoming Investor Conferences |
| Aug 19, 2025 | finance.yahoo.com | 89bio, Inc. (ETNB) Reports Second-Quarter Results; Leerink Partners and Citi Maintain ‘Buy’ Ratings |
| Aug 7, 2025 | finance.yahoo.com | 89bio Reports Second Quarter 2025 Financial Results and Corporate Updates |
| Aug 4, 2025 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Jul 9, 2025 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Jun 6, 2025 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Jun 4, 2025 | finance.yahoo.com | 89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference |
| May 13, 2025 | finance.yahoo.com | Why 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy Now |
| May 9, 2025 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| May 6, 2025 | finance.yahoo.com | 89bio to Participate in Upcoming Investor Conferences |
| May 1, 2025 | finance.yahoo.com | 89bio Reports First Quarter 2025 Financial Results and Corporate Updates |
| Mar 13, 2025 | finance.yahoo.com | Citi says SMid biotechs alternative to large caps as it starts coverage |
| Mar 12, 2025 | finance.yahoo.com | Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now |
| Mar 3, 2025 | finance.yahoo.com | 89bio to Participate in the Leerink Partners Global Healthcare Conference |
| Feb 27, 2025 | finance.yahoo.com | 89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates |
| Feb 20, 2025 | finance.yahoo.com | Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High? |
| Feb 20, 2025 | finance.yahoo.com | Should You Buy 89BIO (ETNB) After Golden Cross? |
| Feb 6, 2025 | finance.yahoo.com | Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership |
| Feb 3, 2025 | finance.yahoo.com | 89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| Jan 29, 2025 | finance.yahoo.com | 89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants |
| Jan 28, 2025 | www.fool.com | Why 89bio Stock Lagged the Market Today |
| Jan 27, 2025 | finance.yahoo.com | 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants |
| Jan 27, 2025 | finance.yahoo.com | Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study |
| Jan 13, 2025 | finance.yahoo.com | 89bio Provides Business Update and Outlook for 2025 |
| Jan 7, 2025 | finance.yahoo.com | New Strong Sell Stocks for January 7th |
| Dec 19, 2024 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Dec 4, 2024 | finance.yahoo.com | Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? |
| Nov 29, 2024 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Nov 26, 2024 | finance.yahoo.com | 89bio to Participate in the 7th Annual Evercore HealthCONx Conference |
| Nov 15, 2024 | finance.yahoo.com | 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 |
| Nov 13, 2024 | finance.yahoo.com | 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants |
| Nov 12, 2024 | finance.yahoo.com | 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants |
| Nov 7, 2024 | finance.yahoo.com | 89bio Reports Third Quarter 2024 Financial Results and Corporate Updates |
| Nov 5, 2024 | finance.yahoo.com | 89bio to Participate in the UBS Global Healthcare Conference |
| Nov 2, 2024 | finance.yahoo.com | Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH |
| Nov 1, 2024 | finance.yahoo.com | Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH |
| Oct 18, 2024 | finance.yahoo.com | Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings |
| Oct 17, 2024 | finance.yahoo.com | State Street Corp's Strategic Acquisition in 89bio Inc |
| Oct 15, 2024 | finance.yahoo.com | 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024 |
| Oct 11, 2024 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Sep 30, 2024 | finance.yahoo.com | 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference |
| Sep 19, 2024 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Sep 16, 2024 | finance.yahoo.com | 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer |
| Aug 29, 2024 | finance.yahoo.com | 89bio to Participate in Upcoming Investor Conferences |
| Aug 9, 2024 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Aug 7, 2024 | finance.yahoo.com | 89bio Appoints Francis Sarena as Chief Operating Officer |
| Aug 5, 2024 | finance.yahoo.com | 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors |
| Jul 12, 2024 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Jun 14, 2024 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| May 22, 2024 | finance.yahoo.com | 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress |
| May 14, 2024 | finance.yahoo.com | 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis |
| May 10, 2024 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| May 10, 2024 | finance.yahoo.com | 89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials |
| May 9, 2024 | finance.yahoo.com | ‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks |
| May 9, 2024 | finance.yahoo.com | 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update |
| May 8, 2024 | finance.yahoo.com | 89bio to Participate in the BofA Securities 2024 Health Care Conference |
| May 2, 2024 | finance.yahoo.com | 89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH |
| Apr 17, 2024 | finance.yahoo.com | 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors |
| Apr 17, 2024 | finance.yahoo.com | 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors |
| Apr 11, 2024 | www.fiercepharma.com | 89bio lines up China CDMO to build API plant for commercial production of MASH candidate |
| Apr 5, 2024 | finance.yahoo.com | 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Apr 3, 2024 | finance.yahoo.com | 89bio Inc CEO Rohan Palekar Sells 52,718 Shares |
| Mar 27, 2024 | finance.yahoo.com | 89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis |
| Mar 18, 2024 | www.wsj.com | Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That |
| Mar 13, 2024 | finance.yahoo.com | 13 Best Biotech Stocks To Buy Under $20 |
| Mar 12, 2024 | finance.yahoo.com | 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis |
| Mar 8, 2024 | finance.yahoo.com | 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| Mar 5, 2024 | finance.yahoo.com | 89bio to Participate in the Leerink Partners Global Biopharma Conference |
| Mar 5, 2024 | finance.yahoo.com | Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study |
| Mar 5, 2024 | finance.yahoo.com | Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade |
| Mar 5, 2024 | finance.yahoo.com | 89BIO (ETNB) Just Overtook the 200-Day Moving Average |
| Mar 4, 2024 | finance.yahoo.com | Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs |
| Mar 4, 2024 | finance.yahoo.com | Why Akero Rocketed — And Rival 89bio Topped It — On Results In Liver Disease Treatment |
| Mar 2, 2024 | finance.yahoo.com | 89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... |
| Feb 29, 2024 | finance.yahoo.com | 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates |
| Feb 22, 2024 | finance.yahoo.com | 11 Best Small-Cap Growth Stocks to Invest In |
| Feb 6, 2024 | finance.yahoo.com | 89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference |